Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 31 Aug 2019
Contacts: Elaine Gao, Managing Editor, firstname.lastname@example.org
Ellie Liang, Editor, email@example.com
Title: The mechanism and regulation of epithelial-mesenchymal transition in cancer stem cells
Authors: Shihori Tanabe1), Sabina Quader2), Horacio Cabral3), Ryuichi Ono4)
Affiliations: 1)Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences
2)Innovation Centre of NanoMedicine (iCONM)
3)Department of Bioengineering, Graduate School of Engineering, The University of Tokyo
4)Division of Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences
Abstract: The mechanism of epithelial-mesenchymal transition (EMT) consists of cellular phenotypic transition from epithelial to mesenchymal status. The cells exhibiting EMT exist in cancer stem cell (CSC) population, which is involved in drug resistance. The signaling pathways are dynamically regulated by microRNAs in EMT and CSCs. The recent progress in nano molecules has arisen the possibility to target CSCs with nano-particles. In this review article, we focused on the mechanism of CSCs and EMT, especially into the signaling pathways in EMT, regulation of EMT and CSCs by microRNAs and nano-particles.
Title: Current therapeutics targeting breast cancer stem cells
Authors: Dong-Xu Liu et al.
Affiliations: Auckland University of Technology, New Zealand.
Abstract: Cancer stem cells are believed to drive tumour initiation, progression and metastasis, and confer resistance to radiation and chemotherapy. Cancer stem cells-targeting has been shown to be a promising strategy for the management and eradication of many types of cancers. There are currently a number of agents that target breast cancer stem cells in preclinical models and in clinical trials. The review will summarise the most recent development of these potential therapeutics and discuss the limitations and challenges.